From the study, to your point: > To assess the translational potential of the intranasal neomycin approach in humans, we conducted a small pilot randomized, do

From the study, to your point: > To assess the translational potential of the intranasal neomycin approach in humans, we conducted a small pilot randomized, double-blind, placebo-controlled study involving healthy human participants. > For the experimental arm (n = 12) > For the placebo arm (n = 7) > One out of 21 participants experienced signs of an adverse event after 2 doses which self-resolved after a few days and self-withdrew from the study early. Upon examination of their medical record, it was found that the participant had a history of allergic reactions to various medications (not specific to study drug). Another participant’s nasal samples could not be used due to technical issues. All other 19 participants tolerated the treatment well and did not experience any adverse events from the study.